This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

TriReme Announces A New Round Of Financing Totalling US$18 Million

PLEASANTON, Calif., Nov. 27, 2012 /PRNewswire/ -- TriReme Medical, Inc. and its affiliates (TriReme) announced today a new round of financing that brings a total of US$18 million into the group. The round is led by Luminor Capital of Singapore and includes major existing investors and new Asian investors. TriReme provides a range of innovative solutions for complex lesions and proceeds of the new round will go toward developing TriReme's pipeline of unique dilatation catheters and expanding its commercial infrastructure worldwide.

"We are thrilled to have this major support from Asia in our efforts to create a next generation of interventional devices, " stated Eitan Konstantino, Ph.D., President and CEO of TriReme Medical. "We share a vision of leaving no implant behind and will continue to focus on the large Asian markets in addition to the US."

"TriReme has demonstrated significant commercial and technical progress despite many challenges that the medical device community is facing," said Mr. Michael Kleine representing TriReme's board of directors. "Together with our new partners, we are looking forward to supporting the company in the commercialization of its breakthrough technologies."

In a related announcement, TriReme welcomes Mr. John Borrell as Vice President of Sales. Mr. Borrell is a seasoned sales executive with vast experience including senior management positions held at Covidien, CSI, and FoxHollow.

About TriReme Medical, Inc. Based in Pleasanton, California and Singapore, TriReme Medical, Inc. is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. The company is focused on the US and the emerging Asian markets.

SOURCE TriReme Medical, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs